FDA Requires Label Changes for Flu Vaccines to Highlight Latex Concerns
Share FDA Requires Label Changes for Flu Vaccines to Highlight Latex Concerns. Alterations Will Affect Supply of GSK's Fluarix, Delay Sanofi's Fluzone
American Family Physician, 08/27/2010 Free full text
Manufacturers Sanofi Pasteur and GlaxoSmithKline are informing physicians about changes to the prescribing information of their seasonal influenza vaccines. The changes reflect concerns that the tip caps of flu vaccine products shipped in prefilled syringes may contain natural rubber latex, which can cause allergic reactions in latex–sensitive individuals.